Literature DB >> 24389868

Tuberculosis elimination: theory and practice in Europe.

Lia D'Ambrosio1, Masoud Dara, Marina Tadolini, Rosella Centis, Giovanni Sotgiu, Marieke J van der Werf, Mina Gaga, Daniela Cirillo, Antonio Spanevello, Mario Raviglione, Francesco Blasi, Giovanni Battista Migliori.   

Abstract

Although Europe identified the pathway to tuberculosis (TB) elimination in 1990, no information on programmes for country preparedness is available. A questionnaire investigating TB elimination activities was submitted to 38 national TB programme representatives of low TB incidence (<20 cases per 100 000 population) European countries/territories of the World Health Organization European region. Out of 31 providing a complete answer, 17 (54.8%) reported to have a dedicated national TB programme, 20 (64.5%) a national plan including TB elimination (13 (41.9%) including targets), 22 (71%) guidelines, 14 (45.2%) a specific budget for TB activities, and 23 (74.2%) TB reference centres. All countries reported having case-based electronic TB surveillance, 19 (61.3%) perform regular supervision, 12 (38.7%) have a monitoring and evaluation plan and five (16.1%) perform modelling. In three countries (9.7%), TB health services are free for insured individuals only. In 22 countries/territories (71%) not all TB drugs were available, while in 12 (38.7%) drug stock-outs have been described. Although high-risk group screening for latent TB infection is performed by the majority of countries, only 6 (19.4%) provided figures on preventive treatment completion rates. Not all elements identified as essential for country preparedness to achieve TB elimination are available in the countries surveyed.

Entities:  

Mesh:

Year:  2014        PMID: 24389868     DOI: 10.1183/09031936.00198813

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  32 in total

1.  A new free-cost e-service supporting clinicians to manage their difficult-to-treat TB cases: the ERS-WHO TB consilium.

Authors:  Lia D'Ambrosio; Marina Tadolini; Rosella Centis; Giovanni Battista Migliori
Journal:  J Thorac Dis       Date:  2015-07       Impact factor: 2.895

2.  Classification of drugs to treat multidrug-resistant tuberculosis (MDR-TB): evidence and perspectives.

Authors:  Adrian Rendon; Simon Tiberi; Anna Scardigli; Lia D'Ambrosio; Rosella Centis; Jose A Caminero; Giovanni Battista Migliori
Journal:  J Thorac Dis       Date:  2016-10       Impact factor: 2.895

3.  Tuberculosis in Gulf Health Council Member States: Opportunities and Challenges Towards TB elimination.

Authors:  Salah T Al Awaidy; Faryal Khamis
Journal:  Oman Med J       Date:  2018-05

4.  Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis.

Authors:  Xin Zhang; Matthew E Falagas; Konstantinos Z Vardakas; Rui Wang; Rong Qin; Jin Wang; Youning Liu
Journal:  J Thorac Dis       Date:  2015-04       Impact factor: 2.895

5.  Performance of a lateral flow immunochromatography test for the rapid diagnosis of active tuberculosis in a large multicentre study in areas with different clinical settings and tuberculosis exposure levels.

Authors:  Selene Manga; Rocio Perales; Maria Reaño; Lia D'Ambrosio; Giovanni Battista Migliori; Massimo Amicosante
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

6.  The impact of novel tests for tuberculosis depends on the diagnostic cascade.

Authors:  Amanda Y Sun; Claudia M Denkinger; David W Dowdy
Journal:  Eur Respir J       Date:  2014-09-03       Impact factor: 16.671

7.  Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.

Authors:  Payam Nahid; Sundari R Mase; Giovanni Battista Migliori; Giovanni Sotgiu; Graham H Bothamley; Jan L Brozek; Adithya Cattamanchi; J Peter Cegielski; Lisa Chen; Charles L Daley; Tracy L Dalton; Raquel Duarte; Federica Fregonese; C Robert Horsburgh; Faiz Ahmad Khan; Fayez Kheir; Zhiyi Lan; Alfred Lardizabal; Michael Lauzardo; Joan M Mangan; Suzanne M Marks; Lindsay McKenna; Dick Menzies; Carole D Mitnick; Diana M Nilsen; Farah Parvez; Charles A Peloquin; Ann Raftery; H Simon Schaaf; Neha S Shah; Jeffrey R Starke; John W Wilson; Jonathan M Wortham; Terence Chorba; Barbara Seaworth
Journal:  Am J Respir Crit Care Med       Date:  2019-11-15       Impact factor: 21.405

8.  Tuberculosis screening using ability to provide sputum in an endemic emergency department.

Authors:  Eduardo Ticona; Moises A Huaman; Luz Maria Huaroto; Marcos Burgos; Meghan Brett; Rod Escombe; David A J Moore
Journal:  Eur Respir J       Date:  2015-10-22       Impact factor: 16.671

9.  Benefit of treatment of latent tuberculosis infection in individual patients.

Authors:  Kyle Fluegge
Journal:  Eur Respir J       Date:  2016-05       Impact factor: 16.671

10.  Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

Authors:  Payam Nahid; Susan E Dorman; Narges Alipanah; Pennan M Barry; Jan L Brozek; Adithya Cattamanchi; Lelia H Chaisson; Richard E Chaisson; Charles L Daley; Malgosia Grzemska; Julie M Higashi; Christine S Ho; Philip C Hopewell; Salmaan A Keshavjee; Christian Lienhardt; Richard Menzies; Cynthia Merrifield; Masahiro Narita; Rick O'Brien; Charles A Peloquin; Ann Raftery; Jussi Saukkonen; H Simon Schaaf; Giovanni Sotgiu; Jeffrey R Starke; Giovanni Battista Migliori; Andrew Vernon
Journal:  Clin Infect Dis       Date:  2016-08-10       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.